Physician profile
Dmitri Aleksenko
NPI 1255718946
$6,209.46
in general payments reported to CMS, 2019-2025
25 companies · $14.37 in 2025
The $14.37 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $518 · 2021: $2,008 · 2022: $1,955 · 2023: $1,665 · 2024: $49.56 · 2025: $14.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.45 | 2021-2023 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $684.70 | 2021-2023 | Nuplazid |
| Genzyme Corporation | $572.38 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $444.30 | 2021 | |
| Amgen INC. | $367.60 | 2020-2025 | Uplizna, Aimovig |
| Alexion Pharmaceuticals, INC. | $327.81 | 2020-2023 | Ultomiris |
| Allergan, INC. | $307.95 | 2020-2022 | |
| Lilly USA, LLC | $257.93 | 2021-2023 | Emgality, Amyvid |
| Biogen, INC. | $249.32 | 2020-2023 | Vumerity, Tysabri |
| Pfizer INC. | $236.61 | 2023-2024 | |
| Celgene Corporation | $215.83 | 2022-2023 | Zeposia |
| Genentech USA, INC. | $165.16 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $160.04 | 2022-2023 | Ingrezza, Ongentys |
| Mallinckrodt Hospital Products INC. | $114.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.41 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $86.15 | 2021-2023 | Nourianz |
| Novartis Pharmaceuticals Corporation | $85.08 | 2022-2023 | |
| Horizon Therapeutics Plc | $76.77 | 2022-2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $73.87 | 2022 | |
| Mdd US Operations, LLC | $59.47 | 2023 | Xadago, Apokyn |
| Tg Therapeutics, INC. | $42.46 | 2023-2024 | |
| Lundbeck LLC | $41.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.51 | 2022 | |
| Adamas Pharmaceuticals, INC. | $32.94 | 2021 | |
| Eisai INC. | $29.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Aleksenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.